CATALENT, INC.

(CTLT)
  Report
Real-time Estimate Cboe BZX  -  05/18 12:15:06 pm EDT
98.84 USD   -1.91%
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:40 PM
CI
05/04Morgan Stanley Adjusts Catalent's Price Target to $132 from $145, Keeps Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalent to Seek M&A

01/10/2022 | 07:30am EDT

Catalent, Inc. (NYSE:CTLT) will seek M&A. Chairman and Chief Executive Officer John Chiminski said, "we grow at the high end of our long-term guidance and add some additional tuck-in M&A".


ę S&P Capital IQ 2022
All news about CATALENT, INC.
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time..
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/04Morgan Stanley Adjusts Catalent's Price Target to $132 from $145, Keeps Overweight Rati..
MT
05/04UBS Adjusts Catalent Price Target to $145 From $155, Maintains Buy Rating
MT
05/04KeyBanc Adjusts Catalent's Price Target to $125 From $155, Keeps Overweight Rating
MT
05/03SECTOR UPDATE : Health Care Stocks Rise on Tuesday
MT
05/03SECTOR UPDATE : Health Care Advance Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care Stocks Advancing on Tuesday, Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care
MT
05/03Catalent Reports Increase in Fiscal Q3 Adjusted Net Income, Revenue; Raises FY2022 Targ..
MT
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Financials (USD)
Sales 2022 4 857 M - -
Net income 2022 481 M - -
Net Debt 2022 3 136 M - -
P/E ratio 2022 37,4x
Yield 2022 -
Capitalization 18 058 M 18 058 M -
EV / Sales 2022 4,36x
EV / Sales 2023 3,95x
Nbr of Employees 17 300
Free-Float 99,7%
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 100,76 $
Average target price 134,92 $
Spread / Average Target 33,9%
EPS Revisions
Managers and Directors
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli Vice President-Operations
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.-21.30%18 058
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868